Insider Selling: Stevanato Group (NYSE:STVN) Director Sells 2,045 Shares of Stock

Stevanato Group S.p.A. (NYSE:STVN) Director Elisabetta Magistretti sold 2,045 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of €20.09, for a total value of €41,084.05. Following the transaction, the director owned 2,930 shares in the company, valued at €58,863.70. This represents a 41.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Stevanato Group Stock Performance

Shares of STVN stock traded up €0.38 during trading hours on Monday, hitting €20.65. The stock had a trading volume of 501,629 shares, compared to its average volume of 541,629. The firm has a market capitalization of $6.25 billion, a PE ratio of 36.87, a PEG ratio of 1.70 and a beta of 0.77. Stevanato Group S.p.A. has a twelve month low of €12.89 and a twelve month high of €28.00. The stock’s 50 day moving average is €18.80 and its 200 day moving average is €16.97. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.61 and a quick ratio of 1.08.

Stevanato Group (NYSE:STVN) last announced its earnings results on Friday, May 8th. The company reported €0.11 EPS for the quarter, missing analysts’ consensus estimates of €0.12 by (€0.01). Stevanato Group had a net margin of 10.99% and a return on equity of 10.43%. The business had revenue of €273.57 million during the quarter. During the same quarter last year, the firm earned $0.10 earnings per share. Stevanato Group’s revenue for the quarter was up 6.6% on a year-over-year basis. As a group, research analysts forecast that Stevanato Group S.p.A. will post 0.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Stevanato Group

Several hedge funds and other institutional investors have recently bought and sold shares of STVN. First Bank & Trust grew its stake in Stevanato Group by 3.4% in the 2nd quarter. First Bank & Trust now owns 18,417 shares of the company’s stock valued at $333,000 after acquiring an additional 603 shares during the period. Fifth Third Bancorp grew its holdings in shares of Stevanato Group by 22.6% during the first quarter. Fifth Third Bancorp now owns 4,196 shares of the company’s stock worth $58,000 after buying an additional 773 shares in the last quarter. GW&K Investment Management LLC grew its position in shares of Stevanato Group by 76.2% in the fourth quarter. GW&K Investment Management LLC now owns 2,440 shares of the company’s stock valued at $49,000 after purchasing an additional 1,055 shares in the last quarter. Pathstone Holdings LLC increased its stake in shares of Stevanato Group by 1.5% in the 3rd quarter. Pathstone Holdings LLC now owns 71,178 shares of the company’s stock worth $1,833,000 after acquiring an additional 1,067 shares during the last quarter. Finally, Mariner LLC raised its stake in Stevanato Group by 6.9% during the third quarter. Mariner LLC now owns 25,447 shares of the company’s stock worth $655,000 after purchasing an additional 1,638 shares during the period.

Analyst Upgrades and Downgrades

Several research firms recently commented on STVN. TD Cowen upgraded shares of Stevanato Group to a “strong-buy” rating in a research report on Wednesday, June 17th. Wolfe Research started coverage on Stevanato Group in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $21.00 price objective on the stock. Finally, Weiss Ratings raised shares of Stevanato Group from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 16th. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Stevanato Group presently has a consensus rating of “Buy”.

About Stevanato Group

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.